ADMA
ADMA Biologics, Inc.
NASDAQ · USHealthcareBiotechnology
$8.75+0.46%
Price as of Jul 20, 2026
ADMA financials
ADMA Biologics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $510.2M | $426.5M | $258.2M | $154.1M |
| Cost of revenue | $217.4M | $206.9M | $169.3M | $118.8M |
| Gross profit | $292.8M | $219.6M | $88.9M | $35.3M |
| Operating expenses | $101.3M | $80.6M | $67.3M | $74.6M |
| Operating income | $191.4M | $139.0M | $21.6M | -$39.4M |
| Net income | $146.9M | $197.7M | -$28.2M | -$65.9M |
| EBITDA | $197.9M | $147.7M | $5.1M | -$39.5M |
| Basic EPS | $0.62 | $0.85 | $-0.13 | $-0.43 |
| Diluted EPS | $0.60 | $0.81 | $-0.13 | $-0.43 |
| Balance sheet | ||||
| Cash & equivalents | $87.6M | $103.1M | $51.4M | $86.5M |
| Total assets | $624.2M | $488.7M | $329.2M | $348.5M |
| Total liabilities | $146.9M | $139.7M | $194.0M | $196.5M |
| Stockholders’ equity | $477.3M | $349.0M | $135.2M | $152.0M |
| Total debt | $79.9M | $82.1M | $141.4M | $154.4M |
| Net debt | -$7.7M | -$21.0M | $90.1M | $67.9M |
| Cash flow | ||||
| Operating cash flow | $50.4M | $118.7M | $8.8M | -$59.5M |
| Capital expenditure | -$22.6M | -$8.6M | -$5.0M | -$13.9M |
| Free cash flow | $27.8M | $110.1M | $3.8M | -$73.4M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | -$31.9M | $0.00 | -$1.4M | $0.00 |